Drugs for improving cerebral circulation, cerebral metabolism and memory containing as the active ingredient a phenylalkanoylamine derivative or its salt represented by general formula (I) (wherein A represents a 1,3-thiazolin-3-yl group, a 1,2,3,6-tetrahydropyridin-1-yl group, a morpholino group, a thiomorpholin-4-yl group or a 3-pyrrolin-1-yl group, R¹ and R² may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a nitro group, an amino group or (α) (wherein R³ and R⁴ each represents a lower alkyl group or, when taken together, they represent a 5- or 6-membered heterocyclic group together with the nitrogen atom), and n represents an integer of 2 to 6) and novel phenylalkanoylamine derivatives among the compounds represented by (I), and a process for their preparation are disclosed. The above drugs are useful for treating sequelae of cerebral hemorrhage, sequelae of cerebral infarction, arterial aclerosis of brain, sequelae of subarachnoidal hemorrhage, sequelae of head trauma, sequelae of cerebral operation, dementia of cerebral vessel origin, Parkinson's disease, Alzheimer's disease, Pick's disease, sequelae of hypoxia, alcoholic cerebral diseases, etc.